• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form NT 10-Q filed by Fonar Corporation

    2/14/25 4:18:30 PM ET
    $FONR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $FONR alert in real time by email
    NT 10-Q 1 fonar_12b-25.htm

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM 12b-25

     

    NOTIFICATION OF LATE FILING

     

    SEC FILE NUMBER 0-10248

    CUSIP NUMBER 344437-10-8

     

    (Check One): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K
      [X] Form 10-Q [ ] Form N-SAR [ ] Form N-CSR

     

    For Period Ended: December 31, 2024

     

    [ ] Transition Report on Form 10-K

    [ ] Transition Report on Form 20-F

    [ ] Transition Report on Form 11-K

    [ ] Transition Report on Form 10-Q

    [ ] Transition Report on Form N-SAR

     

     For the Transition Period Ended: _________________

     

     

    NOTHING IN THIS FORM SHALL BE CONSTRUED TO IMPLY THAT THE COMMISSION HAS VERIFIED ANY INFORMATION CONTAINED HEREIN.

     

    If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

    ________________________________________________________________

     

    Part I - REGISTRANT INFORMATION

     

      FONAR CORPORATION  
      Full Name of Registrant  
         
      RAANEX II CORPORATION  
      Former Name if Applicable  
         
      110 MARCUS DRIVE  
     

    Address of Principal Executive Office

    (Street and Number)

     
         
      MELVILLE, NY 11747  
      City, State and Zip Code  

     

     
     

     

     

     

    PART II - RULES 12b-25(b) AND (c)

     

    If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

     

     

    (a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense; 

       
    [X] (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
       
      (c) The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

     

     

    PART III – NARRATIVE

     

    State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report of portion thereof, could not be filed within the prescribed time period.

     

    The Company has experienced unexpected delays and requires additional time to finalize the financial and narrative portions of the Form 10-Q. We expect to file within the required report within the allotted extension.

     

    PART IV – OTHER INFORMATION

     

    (1) Name and telephone number of person to contact in regard to this notification

     

    JOHN P. COLLINS  (631)  694-2929
    (Name)  (Area Code)  (Telephone Number)

     

    (2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).

     

    [X] Yes [ ] No

     

    (3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

     

    [ ]Yes [X] No

     

     If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

     

     
     

     

      FONAR CORPORATION  
      (Name of Registrant as Specified in Charter)  

     

    has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: February 14, 2025

    By /s/ TIMOTHY R. DAMADIAN,

    Timothy R. Damadian, President and CEO

     

     

    Get the next $FONR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $FONR

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $FONR
    Leadership Updates

    Live Leadership Updates

    See more
    • FONAR Board of Directors Appoints Independent Director

      Melville, New York--(Newsfile Corp. - March 20, 2023) - FONAR Corporation (NASDAQ:FONR), The Inventor of MR Scanning, today announced that its board of directors appointed Jessica Maher as a replacement independent director to a vacancy on the Company's board of directors and audit committee.Timothy Damadian, chairman, president and CEO of FONAR, said, "FONAR's primary source of income and growth is attributable to its diagnostic imaging management subsidiary, Health Management Company of America (HMCA). As a management company, HMCA bills and collects for all services rendered at HMCA-managed and HMCA-owned facilities. These facilities, all of them located in New York and Florida and coll

      3/20/23 11:37:00 AM ET
      $FONR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Fonar Board of Directors Appoints Independent Director

      Melville, New York--(Newsfile Corp. - November 23, 2021) - FONAR Corporation (NASDAQ:FONR), The Inventor of MR Scanning, today announced that on November 17, 2021, its board of directors appointed John Collins as a replacement independent director to a vacancy on the Company's board of directors and audit committee.Timothy Damadian, president and CEO of FONAR, said, "Our primary source of income and growth is attributable to FONAR's diagnostic imaging management subsidiary, Health Management Company of America (HMCA). Mr. Collins' extensive experience in dealing with insurance companies will be very helpful to HMCA. As a management company, HMCA bills and collects for all services rendered

      11/23/21 2:07:00 PM ET
      $FONR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $FONR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Fonar Announces Fiscal 2025 Financial Results for 3rd Quarter and Nine-Month Period

      Net Income increased 25% to $3.1 million for the quarter ended March 31, 2025 as compared to the quarter ended March 31, 2024. Income from Operations for the quarter ended March 31, 2025 decreased 2% to $3.7 million as compared to the quarter ended March 31, 2024. Diluted Net Income Per Common Share Available to Common Stockholders increased 37% to $0.37 per share for the quarter ended March 31, 2025 as compared to the quarter ended March 31, 2024.Total Revenues-Net increased 6% to $27.2 million for the quarter ended March 31, 2025 as compared to the quarter ended March 31, 2024. Total Cash, Cash Equivalents and Short-Term Investments decreased 4% to $54.4 million at March 31, 2025 as compar

      5/15/25 7:00:00 AM ET
      $FONR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Fonar Announces Six Month and 2nd Quarter Financial Results for Fiscal 2025

      MRI scan volume at HMCA managed sites increased 7% to 79,207 scans during the six-month period ended December 31, 2024, versus 73,776 scans for the six-month period ended December 31, 2023. MRI scan volume at HMCA owned sites decreased 4% to 26,961 scans during the six-month period ended December 31, 2024, versus 28,214 scans for the six-month period ended December 31, 2023.Cash and Cash Equivalents and Short-term Iinvestments decreased 5% to $53.7 million at December 31, 2024, versus the fiscal year ended June 30, 2024. Total Revenues-Net for the six-month period ended December 31, 2024, decreased by 3% to $49.9 million, and for the quarter ended December 31, 2024, decreased by 2% to $25.0

      2/18/25 7:37:00 AM ET
      $FONR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Fonar Announces Financial Results for the 1st Quarter of Fiscal 2025

      Total MRI scan volume at the HMCA-managed sites increased 5% to 53,054 scans for the quarter ending September 30, 2024 versus the corresponding quarter one year earlier. Cash and cash equivalents decreased 4% to $54.2 million at September 30, 2024 as compared to the fiscal year-ended June 30, 2024.Total Revenues - Net decreased by 3% to $25.0 million for the quarter ended September 30, 2024 versus the corresponding quarter one year earlier.Income from Operations decreased 30% to $4.6 million for the quarter ended September 30, 2024 versus the corresponding quarter one year earlier.Net Income decreased 25% to $4.0 million for the quarter ended September 30, 2024 versus the corresponding quart

      11/12/24 7:00:00 AM ET
      $FONR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $FONR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Fonar Corporation

      SC 13G - FONAR CORP (0000355019) (Subject)

      11/14/24 12:27:58 PM ET
      $FONR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G filed by Fonar Corporation

      SC 13G - FONAR CORP (0000355019) (Subject)

      2/13/24 5:04:39 PM ET
      $FONR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by Fonar Corporation (Amendment)

      SC 13G/A - FONAR CORP (0000355019) (Subject)

      2/13/24 4:05:17 PM ET
      $FONR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $FONR
    SEC Filings

    See more
    • SEC Form 10-Q filed by Fonar Corporation

      10-Q - FONAR CORP (0000355019) (Filer)

      5/15/25 2:14:54 PM ET
      $FONR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form DEF 14A filed by Fonar Corporation

      DEF 14A - FONAR CORP (0000355019) (Filer)

      4/7/25 3:03:53 PM ET
      $FONR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Fonar Corporation filed SEC Form 8-K: Results of Operations and Financial Condition

      8-K - FONAR CORP (0000355019) (Filer)

      2/19/25 4:16:47 PM ET
      $FONR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $FONR
    Financials

    Live finance-specific insights

    See more
    • Fonar Announces Financial Results for the 1st Quarter of Fiscal 2025

      Total MRI scan volume at the HMCA-managed sites increased 5% to 53,054 scans for the quarter ending September 30, 2024 versus the corresponding quarter one year earlier. Cash and cash equivalents decreased 4% to $54.2 million at September 30, 2024 as compared to the fiscal year-ended June 30, 2024.Total Revenues - Net decreased by 3% to $25.0 million for the quarter ended September 30, 2024 versus the corresponding quarter one year earlier.Income from Operations decreased 30% to $4.6 million for the quarter ended September 30, 2024 versus the corresponding quarter one year earlier.Net Income decreased 25% to $4.0 million for the quarter ended September 30, 2024 versus the corresponding quart

      11/12/24 7:00:00 AM ET
      $FONR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Fonar Announces Financial Results for Fiscal 2023 3rd Quarter and Nine-Month Period

      Total MRI scan volume at the HMCA-managed sites increased 7% to 49,451 scans for the quarter ended March 31, 2023 versus the corresponding quarter one year earlier. For the nine-month period ended March 31, 2023, 139,339 scans were performed as compared to 140,650 for the corresponding nine-month period one year ago.Net Income increased 37% to $4.5 million for the quarter ended March 31, 2023 and decreased 27% to $9.9 million for the nine-month period ended March 31, 2023. Diluted Net Income Per Common Share Available to Common Stockholders increased 72% to $0.55 for the third fiscal quarter ended March 31, 2023 and decreased 19% to $1.16 for the nine-month period ended March 31, 2023. Tota

      5/15/23 4:05:00 PM ET
      $FONR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Fonar Announces Financial Results for Fiscal 2021 as Diluted EPS Increases 23%

      Total MRI scan volume at the HMCA-managed sites increased 7 % to 178,364 scans for the fiscal year ending June 30, 2021 as compared to the prior year.Total Revenues-Net increased by 5% to $89.9 million for the fiscal year ended June 30, 2021, versus the previous fiscal year.Income from Operations increased 25% to $17.1 million for the fiscal year ended June 30, 2021, versus the previous fiscal year.Net Income increased 17% to $13.7 million for the fiscal year ended June 30, 2021 versus the previous fiscal year.Diluted Net Income per Common Share increased 23% to $1.45 for the fiscal year ended June 30, 2021 versus the previous fiscal year. Book Value Per Share increased by 6% to $20.41 per s

      9/28/21 7:30:00 AM ET
      $FONR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $FONR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Bonanni Luciano B bought $66,110 worth of FONAR CORPORATION COMMON STOCK (4,700 units at $14.07), increasing direct ownership by 9% to 54,253 units

      4 - FONAR CORP (0000355019) (Issuer)

      10/3/22 6:41:44 PM ET
      $FONR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 4: Damadian Timothy Raymond bought $65,205 worth of FONAR CORPORATION COMMON STOCK (4,700 units at $13.87), increasing direct ownership by 12% to 42,700 units

      4 - FONAR CORP (0000355019) (Issuer)

      10/3/22 6:16:39 PM ET
      $FONR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care